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ABSTRACT
Objective: The aim of our study was to evaluate the influence of two complexes of Zn(II)/Au(I) and Zn(II)/Ag(I) with Schiff base ligand (H2Salen) 
obtained from the condensation reaction between salicylaldehyde and ethylenediamine (abbreviated ZnSalenAu, ZnSalenAg) on viability and 
proliferation of cultured human cancer cells.
Methods: The following cell lines were used as model systems: Human cervical carcinoma (cervical carcinoma), A549 (non-small cell lung cancer 
[NSCLC]), glioblastoma multiforme (8MGBA), and A431 (squamous cell carcinoma) and its multidrug-resistant (MDR) clones A431-MDR, A431-MRP, 
and A431-ABCG2 that express mdr1, mrp1, or abcg2 gene, respectively. The investigations were performed by thiazolyl blue tetrazolium bromide test, 
neutral red uptake cytotoxicity assay, crystal violet staining, hematoxylin and eosin staining, double staining with acridine orange, and propidium 
iodide in short-term experiments (12–72 h, with monolayer cell cultures) as well as colony-forming method in long-term experiments (25 days, with 
three dimensional cancer cell colonies).
Results: The results obtained revealed that ZnSalenAu and ZnSalenAg decreased significantly viability and proliferation of the treated cells in a 
time- and concentration-dependent manner being more active as compared to the free ligand H2Salen.
Conclusion: The present study demonstrates for the 1st time the ability of two heterometallic complexes ZnSalenAu and ZnSalenAg to decrease 
significantly viability and proliferation of cultured cell lines established from some of the most common and aggressive human cancers (NSCLC, 
carcinoma of uterine cancer, 8MGBA, and squamous cell carcinoma) as well as MDR cancer cells.
Keywords: Cytotoxic activity, Human cancer cell lines, H2Salen, Schiff bases, Zn(II)/Au(I), Zn(II)/Ag(I) complexes.
INTRODUCTION
Despite undoubted success in the early diagnosis, prevention, and 
treatment of cancer (at least some kinds), neoplastic diseases continue 
to be among the leading causes of morbidity and mortality worldwide 
with approximately 14.1 million new cases and 8.2 death cases in 
2012 [1,2]. Chemotherapy is an important therapeutic strategy for 
cancer treatment, but its success is limited due to various obstacles 
including tumor heterogeneity, intrinsic or acquired (multi) drug 
resistance (MDR) of cancer cells, and severe side/toxic reactions. Hence, 
there is a constant need to develop effective new antitumor agents [3,4].
The discovery of the antitumor properties of cisplatin, and later of 
carboplatin and oxaliplatin, encouraged efforts of scientists to search 
for other metals and metal compounds with pronounced antineoplastic 
activity and opened a new page in the development of medicinal 
chemistry and experimental oncopharmacology [5,6].
Gold and silver have been used for medicinal purposes for thousands of 
years. The antimicrobial activity of silver has been known since ancient 
times, but there are also data about the anticancer activity of silver 
compounds [7-11].
Even in the 19th century gold was still considered as “panacea.” The 
modern age of gold in medicine began in the early 20th century when 
Robert Koch discovered the antituberculosis effect of K[Au(CN)2] and 
Jacques Forestier started to use thiolate gold salts for the treatment 
of rheumatoid arthritis [5,12]. Recent findings suggest that various 
Au(I) and Au(III) complexes can be potentially useful in cancer 
chemotherapy [13,14].
Zinc is an essential element required for proper activity of >300 
enzymes, 3000 proteins, and over 1000 transcription factors. This 
metal plays an important role in key biological processes including DNA 
replication and transcription, gene expression and genome integrity, 
normal functioning of the immune, and central nervous system [15-18]. 
Zinc deficiency has been associated to various pathological conditions 
such as inflammation, infections, and cancer [17,19,20]. Many research 
groups demonstrate encouraging the antineoplastic potential of zinc 
compounds [21-23]. As an essential element, zinc is expected to be less 
toxic than platinum, for example, gold and silver compounds also show 
relatively low toxicity [24,25].
Schiff bases and their derivatives/metal complexes are also reported to 
express a wide range of biological activities, including antidiabetic and 
antitumor properties [26-30].
The aim of our study was to evaluate the influence of two heterometallic 
complexes ZnSalenAu, ZnSalenAg containing a Schiff base ligand 
(H2Salen) obtained from the condensation reaction between 
salicylaldehyde and ethylenediamine, on viability and proliferation of 
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cultured human cancer cells. The X-ray structure, chemical and spectral 
characterization of the first complex (1∞[{Zn3(Salen)2}{m-Au(CN)2}2] 
denoted ZnSalenAu) was reported in one of our previous paper [31]. 
For this reason, in this work, we report only the synthesis and 
physicochemical characterization of ZnSalenAg.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle’s medium (D-MEM) and fetal bovine serum 
(FBS) were purchased from Gibco-Invitrogen (UK). Dimethyl sulfoxide 
(DMSO), neutral red (NR), crystal violet (CV), and trypsin were obtained 
from AppliChem (Germany); purified agar (Difco) and thiazolyl blue 
tetrazolium bromide (MTT) were from Sigma-Aldrich Chemie GmbH 
(Germany). All sterile plasticware was from Orange Scientific (Belgium).
All starting materials for the synthesis of the complexes 
(salicylaldehyde, ethylenediamine, Zn(NO3)2•4H2O, K[Au(CN)2], 
K[Ag(CN)2]) were reagent grade and used without purification. 
The trinuclear Zn(II) precursors were synthesized by reacting the 
Schiff base [H2Salen - Scheme 1] obtained in situ by condensation of 
salicylaldehyde with ethylenediamine, with zinc(II) nitrate.
Synthesis
ZnSalenAg has been obtained following the same general synthetic 
procedure previously described for (1∞[{Zn3(Salen)2} {m-Au(CN)2}2] 
(ZnSalenAu) [31], using K[Ag(CN)2] instead of K[Au(CN)2]. ZnSalenAg 
was obtained as a yellow precipitate (yield ca. 70%). Single crystals 
suitable for X-ray diffraction could not be obtained. Anal. Calcd for 
C36H28Ag2N8O4Zn3: 41.20% C, 2.67% H, 10.68% N. Found: 41.98% C, 
3.20% H, 9.89% N. infrared (IR) bands (KBr, cm−1): 3043 w, 3010 w, 
2898w, 2185vs (νCN), 1641vs, 1599m, 1541s, 1474s, 1447s, 1392m, 
1339s, 1303s, 1192w, 1152m, 1128s, 1064m, 1051w, 1033m, 997w, 
946m, 903w, 852m, 751s, 738m, 647w.
Physical measurements
IR spectra were recorded as KBr pellets on a JASCO Fourier-transform 
IR 4100 spectrophotometer from 4000 to 400 cm−t. Elemental analyzes 
of carbon, hydrogen, and nitrogen were carried out on a EuroEA 
elemental analyzer. Absorption spectra were recorded with a JASCO 
V-670 spectrophotometer. The photoluminescence measurements 
were carried out at room temperature using a JASCO FP 6500 
spectrofluorometer.
Cell cultures and cultivation
The following human permanent cell lines were used as model systems 
in our study: Human cervical carcinoma (HeLa) (carcinoma of the 
uterine cervix), A549 (non-small cell lung cancer [NSCLC]), glioblastoma 
multiforme (8MGBA), and A431 (squamous cell carcinoma) and its 
MDR clones A431-MDR, A431-MRP, and A431-ABCG2 that express 
mdr1, mrp1, or abcg2 gene, respectively. The freezing and thawing of the 
cells were performed according to the conventional methods [32,33]. 
The cells were grown as monolayer cultures in a D-MEM medium, 
supplemented with 5–10% FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin. The cultures were maintained at 37°C in a humidified CO2 
incubator (Thermo Scientific, HEPA Class 100). For routine passages, 
the cells were detached using a mixture of 0.05% trypsin - 0.02% 
ethylenediaminetetraacetic acid. The experiments were performed 
during the exponential phase of cell growth.
Cytotoxicity assays
The cells were seeded in 96-well flat-bottomed microplates at a 
concentration of 1×104 cells/well. After the cells were grown for 24 h 
to a subconfluent state (~60–70%), the culture medium was removed 
and changed by media modified with different concentrations (0.1, 0.5, 
1, 5, and 10 µg/ml) of the compounds tested. Each concentration was 
applied into 4–8 wells. Samples of cells grown in non-modified medium 
served as controls. After 12, 18, 24, 48, and 72 h of incubation, the effect 
of the compounds on cell viability and proliferation was examined by 
MTT test, NR uptake cytotoxicity assay, and CV staining.
The MTT colorimetric assay of cell survival was performed as described 
by Mosmann [34]. The method consisted of 3 h incubation with MTT 
solution (5 mg MTT in 10 mL D-MEM) at 37°C under 5% carbon dioxide 
and 95% air, followed by extraction with a mixture of absolute ethanol 
and DMSO (1:1, vol/vol) to dissolve the blue formazan.
The NR assay was based on the method of Borenfreund and 
Puerner [35]. To each well-containing corresponding cells a medium 
consisting of NR (50 µg/mL, 0.1 mL) was added. The plate was placed 
in the CO2 incubator for 3 h for the uptake of vital dye. Thereafter, 
the medium with NR was removed, and the cells were washed with 
phosphate saline buffer (PBS, 0.2 mL/well), followed by the addition 
of 0.1 mL 1% acetic acid solution containing 50% ethanol to extract 
the dye from the cells.
The CV assay was based on the method of Saotome et al. [36]. After 
each well was washed with PBS, the cells were fixed and stained 
with 0.4% CV solution in methanol for 30 min. Optical density was 
measured at 540 nm using an automatic microplate reader (TECAN, 
Sunrise™, Austria). Relative cell viability, expressed as a percentage 
of the untreated control (100% viability), was calculated for each 
concentration. Concentration-response curves were prepared and the 
effective cytotoxic concentration (CC) of the compounds CC50 (μM) and 
CC90 (μM) causing, respectively, 50% and 90% reduction of cell viability 
was estimated from these curves. All data points represent an average 
of three independent assays.
Hematoxylin and eosin (HE) staining
The cells were grown on coverslips (3.0−3.5×105 cells/well) in 6-well 
plates in the presence of the compounds tested. Non-treated cells served 
as controls. After 24, 48, and 72 h of incubation, the coverslips were 
removed, washed with PBS, fixed in methanol (2×15 min) and stained 
with HE. Dehydration was performed in increasing concentrations of 
alcohols (70%, 80%, 96%, and 100% ethyl alcohol), followed by xylene 
treatment (2×15 min) and mounting in cedar oil. The microscopic 
preparations were examined under the light microscope (Leika DM 
500B, Wetzlar, Germany).
Double staining with acridine orange (AO) and propidium iodide 
(PI)
The ability of compounds to induce cytopathological changes was 
assessed using double staining with AO and PI according to the 
standard procedures [37]. The cells were grown on coverslips and 
treated as it was described in the previous paragraph. After 24, 48, and 
72 h of incubation, the coverslips were removed and washed with PBS 
for 2 min. Equal volumes of fluorescent dyes containing AO (10 µg/mL 
in PBS) and PI (10 µg/mL in bidistilled water) were added to the cells. Scheme 1: H2Salen structure
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Fresh stained cells were placed on a glass slide and examined under 
a fluorescence microscope (Leika DM 500B, Wetzlar, Germany) within 
30 min before the fluorescent color started to fade.
Colony forming method
Tumor cells (103 cells/well) suspended in 0.45% purified agar in 
D-MEM medium containing different concentrations of the compounds 
examined (ranging from 0.5 to 25 μg/mL) were layered in 24 well 
microplates. The presence/absence of colonies was registered using an 
inverted microscope (Carl Zeiss, Germany) during the period of 25 days. 
Colony inhibitory concentration (CIC, μM) at which the compounds 
tested inhibit completely the ability of tumor cells to grow in a semi-
solid medium was determined.
Statistical analysis
The data are presented as mean±standard error of the mean. Statistical 
differences between control and treated groups were assessed using 
one-way analysis of variance followed by Dunnett post hoc test and 
Origin 6.1™.
RESULTS AND DISCUSSION
Physical and chemical properties
Due to the impossibility of obtaining monocrystals suitable for 
X-ray measurements, we tried to establish the molecular formula of 
ZnSalenAg by correlating the chemical analysis with spectral data.
The IR spectrum of ZnSalenAg (Fig. 1) contains some main bands 
which certify the formation of the complex: 3010 cm−h (νasimC-H), 2898 
cm-H (νsimC-H), 2185 cm-H (νCN bridge), 1641 cm−b (νC=N azomethine), 
1541, 1474, 1447 cm−c (νC=C).
The other small bands are characteristic to the Schiff base ligand. 
Comparing the spectrum of ZnSalenAg with that of the free ligand, 
some slight displacements of the bands were observed, confirming 
its involvement in complexation. Another important information 
regarding the structure of the complex is given by the absence of the 
bands corresponding to nitrate anion that confirm its replacement by 
[Ag(CN)2]− units.
The similarity between the data obtained for ZnSalenAg and those of 
ZnSalenAu [31] encouraged us to propose a similar molecular formula 
for ZnSalenAg: 1∞[{Zn3(Salen)2} {µ-Ag(CN)2}2].
The electronic spectrum of ZnSalenAg shows bands located in the 
200–500 nm region (Fig. 2). These bands are must probably due to a 
superposition of π–π* transitions of the organic ligand that appears at 
higher energies and strong MLCT (d–π*) transitions characteristic for 
dicyanoargentate polymers.
It is known that silver(I) and gold(I) complexes have attracted 
attention in the field of the photophysics of metal complexes. The 
structures constructed through metallophilic interactions are known 
to be potentially luminescent materials [38]. For these reasons, the 
luminescent properties of Schiff-base ligand and ZnSalenAg (in solid 
state), at room temperature, have been investigated (Fig. 3). For 
H2Salen a green emission was observed with the maximum at 504 nm 
by excitation with 370 nm.
The emission spectrum of ZnSalenAg presented in Fig. 3 exhibits 
luminescence with a peak maximum at λem=447 nm, slightly shifted 
compared with that observed for ZnSalenAu (464 nm) [31]. Compared 
with the free ligand, emission of ZnSalenAg is slightly shifted to lower 
wavenumber as a result of coordination of zinc(II) centers to the ligand, and 
the luminescence is most probably due to intraligand 1(π*–π) fluorescence.
Cytotoxic activity
Short-term experiments
The investigations were performed in two steps: (1) The influence of 
the compounds investigated on viability and proliferation of cancer 
(HeLa, A549, 8MGBA, A431, and its clones) cells used as model systems 
in our study was evaluated initially by MTT test - the gold standard 
for cytotoxicity assays. The “concentration - response” curves were 
prepared (examples of such curves are presented in Figs. 4-7) and 
effective concentrations CC50 and CC90 that reduce cell viability by 50% 
and 90%, respectively, as compared to the control, were calculated from 
these curves where possible (Tables 1-3).
The results obtained reveal that ZnSalenAu and ZnSalenAg decrease 
significantly viability and/or proliferation of the treated cells in a 
time- and concentration-dependent manner being more active cytotoxic 
agents as compared to H2Salen. For instance, CC50 of ZnSalenAu and 
ZnSalenAg (determined by MTT, 72 h) were found to be <6.5 µM and 
<7.5 µM, respectively. The experimental design was extended using 
additional methods with different molecular/cellular targets and 
mechanisms of action * NR uptake cytotoxicity assay and CV staining 
Fig. 1: Infrared spectrum of ZnSalenAg
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on HeLa cervical carcinoma cell line, due to its high sensitivity to the 
cytotoxic activity of the examined compounds and wide application as a 
model system in laboratory practice.
The CC50 and CC90 values for HeLa cells measured by MTT, NR, and CV 
assays are presented in Table 1. The cytopathological changes (such 
as reduced cell number, vacuolization of cytoplasm, cell picnosis, and 
apoptotic bodies) in HeLa cells cultured in the presence of ZnSalenAu 
and ZnSalenAg are visualized by HE staining as well as double staining 
with AO and PI (Fig. 8).
Long-term experiments
The MTT, NR, CV, HE, and AO/PI assays demonstrate the “quick” 
(12–72 h) effect of the compounds tested on monolayer (two 
dimensional [2D]) cell cultures whereas the colony-forming method 
reveals their long-term ability to suppress the three dimensional (3D) 
growth of cancer cells. 3D cell cultures have been considered to be 
more physiologically relevant and predictive model systems than 2D 
cell cultures. Various differences between 2D and 3D experimental cell 
models have been reported including response to therapeutic agents, 
demonstrating the advantages of 3D cell culturing [39,40]. It has been 
found in our investigations that both metal complexes completely 
inhibit 3D growth of HeLa cells in a semi-solid medium administered 
at concentrations ≥0.41 µM (0.5 µg/ml, ZnSalenAu) and ≥0.47 µM 
(0.5 µg/ml, ZnSalenAg). Applied independently, H2Salen does not 
inhibit 3D colony-forming ability of HeLa cells.
In this study, we report for the 1st time the ability of ZnSalenAu and 
ZnSalenAg to inhibit the 2D- and 3D-growth of cultured human cancer cells. 
It’s worth mentioning that our model systems used in our experiments 
provoke interest due to the following reasons: (i) Lung cancer is among the 
most frequent and deadly neoplastic diseases. NSCLC is the most common 
form of lung cancer representing about 85% of all cases. In 85–90% of the 
Table 1: CC50 µM and CC90 µM of ZnSalenAu and ZnSalenAg for HeLa cell line
Treatment period (h) Method H2Salen ZnSalenAu ZnSalenAg
12 MTT n.d. 0.52* (3.67)** 3.13 (4.70)
18 n.d. 0.46 (2.64) 2.99 (4.47)
24 n.d. 0.41 (n.d.) 2.89 (4.46)
48 n.d. 0.23 (0.41) 2.59 (4.33)
72 MTT n.d. 0.28 (0.63) 1.76 (4.17)
NR n.d. 0.80 (3.40) 2.04 (4.18)
CV n.d. 2.94 (n.d.) 2.83 (n.d.)
*CC50 µM, **CC90 µM, MTT: Thiazolyl blue tetrazolium bromide test, NR: Neutral red uptake cytotoxicity assay, CV: Crystal violet staining, n.d. - CC50: Respectively, 
CC90 was not determined because at all examined concentrations (0.1–10 µg/ml) the cell viability was >50%, respectively, >10%. CC: Cytotoxic concentration
Table 2: CC50 µM and CC90 µM of ZnSalenAu and ZnSalenAg for 
human A549 and 8MGBA cell lines
A 549 cell line
Treatment period Method H2Salen ZnSalenAu ZnSalenAg
48 MTT n.d. 2.50* (3.91)** 2.54 (7.60)
72 n.d. 6.46 (8.90) 7.32 (9.54)
8MGBA cell line
24 MTT n.d. 1.34 (8.15) 2.74 (4.49)
48 n.d. 0.45 (2.89) 2.75 (4.35)
72 n.d. 0.65 (3.34) 3.19 (4.48)
*CC50 µM, **CC90 µM, MTT: Thiazolyl blue tetrazolium bromide test, 
n.d. - CC50, respectively, CC90, was not determined because at all examined 
concentrations (0.1–10 µg/ml) the cell viability was >50%, respectively, >10%. 
CC: Cytotoxic concentration, 8MGBA: Glioblastoma multiforme
Table 3: CC50 µM and CC90 µM of ZnSalenAu and ZnSalenAg 
against human squamous cell carcinoma cell line A431 and its 
multidrug-resistant clones
Cell line ZnSalenAu ZnSalenAg
MTT, 72 h
A431 0.98* (3.42)** 3.10 (4.38)
A431-MDR1 2.46 (6.28) 2.06 (4.24)
A431-MRP1 2.67 (8.15) 2.28 (4.46)
A431-ABCG2 2.16 (3.60) 3.82 (4.58)
*CC50 µM; **CC90 µM, MTT: Thiazolyl blue tetrazolium bromide test, 
CC: Cytotoxic concentration, 8MGBA: Glioblastoma multiforme. CC: Cytotoxic 
concentration, MDR: Multidrug-resistant
Fig. 2: The UV–visible spectrum of ZnSalenAg
Fig. 3: Solid-state emission spectrum of ZnSalenAg at room 
temperature (λexc=370 nm) (inset - emission spectrum of H2Salen)
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Although both metal complexes are active, the CC50 and CC90 of  ZnSalenAu 
are lower than those of ZnSalenAg. Our preliminary investigations with 
Ru(III) complexes with H2Salen reveal that they possess significantly 
lower cytotoxic activity for HeLa cells as compared to Zn(II)/Au(I) and 
Zn(II)/Ag(I) complexes with the same ligand (not published data).
CONCLUSION
In this study, we report for the 1st time the ability of two heterometallic 
complexes ZnSalenAu and ZnSalenAg containing a Schiff base 
Fig. 5: Concentration-response curves of ZnSalenAu, ZnSalenAg 
and their ligand H2Salen for human non-small cell lung cancer 
(A549) cells evaluated by thiazolyl blue tetrazolium bromide test 
after 48 h treatment period
Fig. 6: Concentration-response curves of ZnSalenAu, for human 
glioblastoma multiforme cells evaluated by thiazolyl blue 
tetrazolium bromide test after 24 h, 48 h, and 72 h treatment 
period
Fig. 7: Concentration-response curves of ZnSalenAu for human 
squamous cell carcinoma cells (A431 parental cell line and its 
drug-resistant clones) evaluated by thiazolyl blue tetrazolium 
bromide test after 72 h treatment period
Fig. 4: Concentration-response curves of ZnSalenAu, ZnSalenAg and their ligand H2Salen for human cervical carcinoma cells evaluated by 
thiazolyl blue tetrazolium bromide test after 24 h (a), 48 h (b), and 72 h (c) treatment period
a b
c
cases, the disease is diagnosed later (IIIB and IV stages) when the patients 
are  inoperable,  and  the  main  treatment  is  conservative  - 
chemotherapy  and/or  radiotherapy  [41];  (ii)  8MGBA  is  a  highly 
aggressive  cancer.  The  survival  rate  of  people  affected  by  this 
disease has remained virtually  unchanged over the past few 
decades and is only 6-12-15 months after the diagnosis despite
 advances in surgical  approaches,  radiation,  and chemotherapy, 
5-year survival remains <3% [42,43]; (iii) drug resistance is 
the main obstacle preventing successful chemotherapy of  cancer. 
The so-called ATP–binding cassette proteins transporters (such as 
the products of mdr1, mrp1, and abcg2 genes) are key players in MDR 
phenomenon [44,45]; (iv) carcinoma of the uterine cervix is among 
the  most  frequent  malignancies  in  women  [46,47].  HeLa  is  the  oldest 
and  the  most  widely  used  cell  culture  model  in  biomedical  research 
[48,49].
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ligand (H2Salen) obtained from the condensation reaction between 
salicylaldehyde and ethylenediamine, to decrease significantly viability 
and proliferation of cultured cell lines established from some of the 
most common and aggressive human cancers (NSCLC, carcinoma of the 
uterine cancer, 8MGBA, and squamous cell carcinoma) as well as MDR 
cancer cells. The cytotoxic activity of the compounds investigated was 
prove by in short-term and long-term experiments using 2D and 3D 
cell cultures and methods with different molecular/cellular targets and 
mechanisms of action. Additional investigations are underway to clarify 
better the antineoplastic potential of ZnSalenAu and ZnSalenAg.
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